NCT07057310Enrolling by invitationPhase 4
Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women
Source: ClinicalTrials.gov · Last updated 20 Jul 2026
Brief summary (registry, in English)
In postmenopausal women, obesity increases the risk of physical function decline, premature aging, and vascular dysfunction. Semaglutide and tirzepatide are potent obesity medications. The goal is to determine the effect of weight loss induced by the new generation of GLP-1 receptor agonists on physical function, aging biomarkers, and vascular function in postmenopausal women with obesity.
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 5 May 2025
- Start date
- May 2025
- Primary completion date
- Dec 2026
- Lead sponsor
- Mayo Clinic
- Diseases
- Obesity
- NCT number
- NCT07057310
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 30
- From May 2025 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Past or current use of menopausal hormone therapy
- \>5% change in weight during the 3 months prior to screening
- Other anti-obesity medication use within the past 3 months
Other illness
- History of chemically induced menopause
- Diabetes
- Cardiovascular disease
- Uncontrolled co-morbidities including inflammatory, autoimmune, infectious, hepatic, gastrointestinal, malignant, or psychiatric disease
- History of bariatric surgery
- History of malignant neoplasms within the past 5 years prior to screening
- Personal or family history of medullary thyroid cancer.
Lab values
- Impaired renal function (GFR ≤29)
Other
- Early or premature menopause
- Thyroid-stimulating hormone ≥7 with low free T4
- Elevated blood pressure (\>170/\>95)
- Current use of supplements known to affect weight
- Wheelchair bound
- Vision loss
Who the study is looking for
- Postmenopausal women (with menopause defined as the cessation of menstrual periods for at least 12 months or history of bilateral oophorecomy)
- Age 46-60 years old
- BMI ≥ 30 kg/m2.
Age in the registry: 46 years to 60 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Florida Coordinator of this site? Confirm its status | Jacksonville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.